A high-level overview of Adamas Trust, Inc. 7% SER G PFD (ADAMZ) stock. View (ADAMZ) real-time stock price, chart, news, analysis, analyst reviews and more.
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable. The deal ...
We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback